CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL).
  
  LEARNING OBJECTIVES

  • Appraise the risk-benefit profiles of the various novel targeted agents currently used in the treatment of chronic lymphocytic leukemia (CLL), and develop strategies to manage the unique toxicities that can occur.
  • Understand the pathophysiology of tumor lysis syndrome (TLS), recognize the disease- and treatment-related risk factors and establish an evidence-based approach for prevention and management.
  • Recognize the increased risk of TLS for patients with CLL who receive venetoclax/obinutuzumab, and implement administration protocols designed to reduce the frequency of this potentially fatal toxicity.
  • Formulate an approach to managing TLS-associated metabolic abnormalities, including knowing when nephrology consultation is warranted.
  • Consider the risk of cardiac side effects for patients with CLL receiving Bruton tyrosine kinase inhibitors, and institute corresponding treatment modifications.
  • Assess the incidence of neutropenia resulting from the use of venetoclax/obinutuzumab, and formulate strategies to manage or mitigate this toxicity.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Gigi Chen, MD
  Diablo Valley Oncology and Hematology Medical Group
  Pleasant Hill, California
  
  No relevant conflicts of interest to disclose.
  
  Ilya Glezerman, MD
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  Clinical Associate Professor
  Weill Cornell Medical College
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Amy Goodrich, CRNP
  Nurse Practitioner

  The Sidney Kimmel Comprehensive Cancer Center
  Johns Hopkins Medicine
  Baltimore, Maryland
  
  No relevant conflicts of interest to disclose.
  
  Dipti Gupta, MD, MPH
  Assistant Attending, Cardiology
  Program Director, Cardio-Oncology Fellowship Program
  Assistant Clinical Professor, Weill Cornell Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Yanjun Ma, MD
  Tennessee Oncology
  Murfreesboro, Tennessee
  
  No relevant conflicts of interest to disclose.
  
  Anthony R Mato, MD, MSCE
  Associate Attending
  Director, Chronic Lymphocytic Leukemia Program
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Octapharma Plasma, Inc, Pharmacyclics LLC; Consulting Agreement: AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma Plasma, Inc, Pharmacyclics LLC, TG Therapeutics Inc, Sunesis Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Celgene Corporation, TG Therapeutics Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Genentech, a member of the Roche Group.
  
  Release date: August 2021
  Expiration date: August 2022